PDSB Share Price | PDS Biotechnology Corp. Stock Analysis & Recommendation

Q: What does PDS Biotechnology Corp. do?

Overview:PDS Biotechnology Corp. is an immuno-oncology company focused on developing clinical-stage immunotherapies for various cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025)Market cap: USD 74.05 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.94Return on Equity: -158.73%Price to Book: 3.31Contact Details:Address: 25B VREELAND ROAD, FLORHAM PARK NJ: 07932Tel: 1 908 5173613Website: https://www.pdsbiotech.com

Q: Is PDS Biotechnology Corp. technically bullish or bearish?

As of 11 September 2025, the technical trend for PDS Biotechnology Corp. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators such as the daily moving averages and the weekly KST both signaling bearish momentum. Additionally, Bollinger Bands are bearish on both weekly and monthly time frames. The MACD shows a mildly bullish stance on weekly and monthly charts, but this is overshadowed by the overall bearish signals. In terms of performance, PDS Biotechnology has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -29.45% versus the S&P 500's 12.22%, and a one-year return of -62.54% compared to 17.14% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

405.14 k

Shareholding (Dec 2025)

FII

1.49%

Held by 32 FIIs

DII

98.26%

Held by 9 DIIs

Promoter

0.26%

How big is PDS Biotechnology Corp.?

22-Jun-2025

As of Jun 18, PDS Biotechnology Corp. has a market capitalization of 74.05 million and reported net sales of 0.00 million with a net profit of -35.50 million over the last four quarters. The balance sheet shows shareholder's funds of 19.00 million and total assets of 45.36 million.

View full answer

What does PDS Biotechnology Corp. do?

22-Jun-2025

PDS Biotechnology Corp. is an immuno-oncology company developing clinical-stage immunotherapies for cancer, classified as a micro-cap with a market cap of $74.05 million and a recent net profit loss of $8 million. The company has no dividend yield and negative return metrics.

View full answer

Who are in the management team of PDS Biotechnology Corp.?

22-Jun-2025

As of March 2022, the management team of PDS Biotechnology Corp. includes Independent Chairman Mr. Stephen Glover, President and CEO Dr. Frank Bedu-Addo, Directors Dr. Otis Brawley, Dr. Ilian Iliev, and Independent Directors Ms. Kamil Ali-Jackson, Mr. DeLyle Bloomquist, and Mr. Gregory Freitag.

View full answer

Is PDS Biotechnology Corp. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, PDS Biotechnology Corp. is in a bearish trend, with key indicators signaling bearish momentum and a year-to-date return of -29.45%, significantly underperforming the S&P 500's 12.22%.

View full answer

Compare PDS Biotechnology Corp. with Similar Stocks

Actinium Pharmaceuticals, Inc.Atara Biotherapeutics, Inc.Alimera Sciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 35 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.87

Return on Equity

-369.02%

Price to Book

3.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

61.74%

6 Months

14.13%

1 Year

-14.73%

2 Years

-68.66%

3 Years

-82.95%

4 Years

-71.28%

5 Years

-75.0%

PDS Biotechnology Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-186.39%

EBIT to Interest (avg)

-16.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.94

Sales to Capital Employed (avg)

Tax Ratio

5.43%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

21.99%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.66

EV to EBIT

-0.82

EV to EBITDA

-0.82

EV to Capital Employed

22.18

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-2712.23%

ROE (Latest)

-369.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 15 Schemes (7.66%)

Foreign Institutions

Held by 32 Foreign Institutions (1.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 5.00% vs 26.61% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-7.30",
          "chgp": "8.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "1.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.60",
          "val2": "-8.00",
          "chgp": "5.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.24% vs 12.35% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.50",
          "val2": "-36.30",
          "chgp": "13.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.30",
          "val2": "4.70",
          "chgp": "12.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.50",
          "val2": "-37.60",
          "chgp": "8.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.70

-7.30

8.22%

Interest

1.10

Exceptional Items

0.00

Consolidate Net Profit

-7.60

-8.00

5.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 5.00% vs 26.61% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-31.50

-36.30

13.22%

Interest

5.30

4.70

12.77%

Exceptional Items

0.00

Consolidate Net Profit

-34.50

-37.60

8.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 8.24% vs 12.35% in Dec 2024

All Annual Results

Company CV

About PDS Biotechnology Corp.

PDS Biotechnology Corp.

Pharmaceuticals & Biotechnology

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Company Coordinates

Company Details

25B VREELAND ROAD , FLORHAM PARK NJ : 07932

Tel: 1 908 5173613

https://www.pdsbiotech.com

Registrar Details